Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
NCT03823131 · Chase Heaton, MD · PHASE2 · terminated · last registry update 2023-05-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Treatment Ineffective” | – | Registry record, Chase Heaton, MD |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IDO1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-08-28Results posted on the registry: Bristol-Myers Squibb, BMS-986205 + Nivolumab (NCT02658890)
- 2023-08-22Results posted on the registry: Edward Kim, IDO1 Inhibitor BMS-986205 + Nivolumab (NCT03695250)
- 2023-06-09Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Ipilimumab (NCT02935634)
- 2023-06-01Results posted on the registry: Bristol-Myers Squibb, Nivolumab + BCG (NCT03519256)
- 2023-06-01Also stopped (terminated): Bristol-Myers Squibb, Nivolumab + BCG (NCT03519256)
- 2023-04-26Results posted on the registry: Incyte Corporation, Nivolumab + Epacadostat (NCT02327078)
- 2023-02-24Results posted on the registry: Roswell Park Cancer Institute, DEC-205/NY-ESO-1 Fusion Protein CDX-1401 + Epacadostat (NCT02166905)
- 2022-12-23Results posted on the registry: National Cancer Institute (NCI), Epacadostat + Pembrolizumab (NCT03602586)
- 2022-12-19Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Ipilimumab (NCT02996110)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision